{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-086629","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.788718+00:00","generated_at":"2026-05-15T22:17:38.643938+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amylyx reports FY2025 net loss of $144.7M; avexitide Phase 3 enrollment complete, topline data Q3 2026","bullets":["Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.","Phase 3 LUCIDITY trial of avexitide in PBH enrollment complete; topline data expected Q3 2026, potential launch 2027.","Cash, equivalents, and short-term investments $317.0M at Dec 31, 2025; cash runway into 2028.","R&D expenses decreased to $90.4M from $104.1M due to lower AMX0035 spending, offset by increased avexitide costs.","Selected AMX0318 (GLP-1 receptor antagonist) as development candidate for PBH; IND filing targeted 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-086629","json":"https://secwatch.observer/filing/0001193125-26-086629.json","markdown":"https://secwatch.observer/filing/0001193125-26-086629.md","text":"https://secwatch.observer/filing/0001193125-26-086629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/0001193125-26-086629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/amlx-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:17:38.643938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}